Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
© Heinemann et al; licensee BioMed Central Ltd. 2011
Received: 29 November 2010
Accepted: 6 June 2011
Published: 6 June 2011
Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity in vitro, in in vivo murine models and in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in combination with other modalities such as chemotherapy, targeted therapy and radiotherapy. In this study, we examine the oncolytic activity of reovirus T3D and chemotherapeutic agents against human prostate cancer cell lines, with particular focus on the highly metastatic cell line PC3 and the chemotherapeutic agent docetaxel. Docetaxel is the standard of care for metastatic prostate cancer and acts by disrupting the normal process of microtubule assembly and disassembly. Reoviruses have been shown to associate with microtubules and may require this association for efficient viral replication.
The effects of reovirus and chemotherapy on in vitro cytotoxicity were investigated in PC3 and Du 145 cells and the interactions between agents were assessed by combination index analysis. An Annexin V/propidium iodide fluorescence-activated cell sorting-based assay was used to determine mode of cell death. The effects of reovirus and docetaxel administered as single agent or combination therapy were tested in vivo in a murine model. The effects of docetaxel and reovirus, alone and together, on microtubule stabilisation were investigated by Western blot analysis.
Variable degrees of synergistic cytotoxicity were observed in PC3 and Du 145 cells exposed to live reovirus and several chemotherapy agents. Combination of reovirus infection with docetaxel exposure led to increased late apoptotic/necrotic cell populations. Reovirus/docetaxel combined therapy led to reduced tumour growth and increased survival in a PC3 tumour bearing mouse model. Microtubule stabilization was enhanced in PC3 cells treated with reovirus/docetaxel combined therapy compared to other reovirus/chemotherapy combinations.
The co-administration of a variety of chemotherapeutic agents with live reovirus was able to enhance cytotoxicity synergistically in vitro. The combination of docetaxel with reovirus also delayed tumour growth and improved survival in vivo. Enhanced microtubule stabilisation following this combination treatment may, in part, explain the mechanism of synergy. These results provide evidence to support the ongoing clinical trials using these agents.
Reoviruses (Respiratory Enteric Orphan viruses) are non-enveloped icosahedral viruses with a segmented double stranded RNA genome. Reoviruses are ubiquitous, non-pathogenic viruses that have innate oncolytic activity in a wide range of human and murine tumour cells. This property correlates with the transformed state of the cell [1, 2] as transformation of immortalized cells which were not tumorigenic in vivo with oncogenes such as Ras, Sos, v-erb and c-myc rendered them susceptible to reovirus oncolysis [3–5]. In normal cells, activation of double-stranded RNA-activated protein kinase system (PKR) prevents significant viral replication; in malignant cells with an activated Ras pathway, up-regulated upstream or downstream components of the cell signaling pathway or up-regulated epidermal growth factor receptor signaling [3, 4, 6], this cellular antiviral response mechanism is perturbed and viral replication occurs leading to cytolysis of the host cell. In view of the high frequency of Ras dysregulation in different cancers , reovirus has potential as a broadly applicable anti-cancer therapeutic. A number of phase I clinical studies of intratumoral or systemic reovirus as a single agent have been completed, with evidence of significant antitumor activity [8, 9]. However, in order to maximise the efficiency of tumour kill, combination therapy with other treatment modalities such as radiation or chemotherapy is likely.
Prostate cancer is one of the most common types of cancer in men, accounting for approximately 24% of new diagnoses and 13% of cancer deaths in the UK . Surgery and radiotherapy may be curative, but significant numbers of patients relapse or present with locally advanced or metastatic disease and are treated with hormonal therapy. However, most subsequently progress and are treated with further hormonal therapy or chemotherapy.
Following several reports of significant activity in prostate cancer [11, 12], docetaxel (taxotere) has become the standard of care first line chemotherapy agent worldwide. Docetaxel is a member of the taxane family and binds with high affinity to tubulin in microtubules, stabilising the microtubule and preventing depolymerisation [13–15]. Mitotic cell division is inhibited by the decrease in free tubulin, and the accumulation of microtubules within the cell leads to the initiation of apoptosis.
Reoviruses have been shown to associate with microtubules  via the core protein μ2  and it has been proposed that efficient reovirus growth in some cell types may be dependent on μ2-mediated recruitment of viral factories to microtubules . The stabilisation of microtubules by docetaxel could be expected to facilitate reovirus replication and enhance the therapeutic potential of the combination.
In this study we have examined the potential for synergistic or additive anticancer effects of combining reovirus with docetaxel in human prostate cell lines. We report this combination leads to enhanced cell death in vitro and reduced tumour growth in vivo providing evidence to support the ongoing clinical trials using these agents together.
The human prostate cancer-derived cell lines PC3, Du 145 and LNCaP were cultured in RPMI 1640 medium (Sigma-Aldrich, Gillingham, UK) at 37°C and 5% CO2. L929, a murine fibroblast-like line, was cultured in DMEM medium (Sigma-Aldrich) at 37°C and 5% CO2. All media were supplemented with 2 mM GlutaMAX-1 supplement (Invitrogen, Paisley, UK), 100 units/mL penicillin/streptomycin (Sigma-Aldrich) and either 10% (v/v) foetal calf serum (FCS; Invitrogen) for routine passage or 2% (v/v) FCS for experimental work.
Reovirus stocks and chemotherapeutic agents
Reovirus type 3 Dearing strain Reolysin® was obtained from Oncolytics Biotech. Inc. (Calgary, Canada). Virus stock titre and virus stability was measured by standard plaque assay of serially diluted samples on L929 cells. Six-well plates were seeded with 1 × 106 L929 cells per well and infected with dilutions of viral stocks. After 3 h incubation at 37°C, the virus solution was removed and the wells were overlaid with a 1:1 mixture of 2% SeaPlaque agarose (Cambrex Bio Science Rockland, Inc, ME) and 2 × MEM (Invitrogen) supplemented to a final concentration of 5% (v/v) FCS, 100 units/mL penicillin/streptomycin and 2 mM GlutaMAX-1. Wells were stained with 500 μL 0.03% neutral red (Sigma-Aldrich) in PBS 72 h post-infection and plaques were counted 3 to 4 h later.
Docetaxel (Sanofi-Aventis), paclitaxel (Bristol-Myers Squibb Company, N.Y.), vincristine sulphate (Tocris Bioscience) and cisplatin (cis diamminedichloroplatinum; Mayne Pharma Plc, UK) were all obtained from Royal Surrey County Hospital pharmacy. Doxorubicin hydrochloride was purchased from Sigma-Aldrich.
In vitro survival assay
Cells were plated in 96-well plates at a density of 5 × 103 cells per well for PC3 and 7.5 × 103 cells per well for Du 145 and LNCaP. After 24 h, they were infected with known dilutions of reovirus, either alone or in combination with a chemotherapeutic agent. Control wells received an equivalent volume of assay medium. After 48 h incubation, cell viability was quantified using the CellTiter 96 AQueous One Solution Cell Proliferation Assay reagent 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS; Promega, Southampton, UK) according to manufacturer's instructions. Briefly, 20 μL of MTS reagent was added to each well and following incubation at 37°C for 1-4 h, absorbance was measured at 490 nm. Survival was calculated as a percent compared to untreated cells.
In vitro synergy assay
The effect of the combination of reovirus and chemotherapy on cell proliferation was assessed by calculating combination-index (CI) values using CalcuSyn software (Biosoft, Ferguson, MO). Derived from the median-effect principle of Chou and Talalay , the CI provides a quantitative measure of the degree of interaction between two or more agents. A CI of 1 denotes an additive interaction, >1 antagonism and <1 synergy. Experiments were performed as described for the in vitro survival assay using 4, 2, 1, 0.5 and 0.25 times the calculated median effective dose (ED50) of each agent in a constant ratio checkerboard design.
Inactivation of reovirus by UV-irradiation and heat
Reovirus was UV inactivated by exposing 50 μL aliquots of viral stock at 1.2 × 1010 pfu/mL to 720 millijoules irradiation using a Stratalinker UV Crosslinker 2400 (Stratagene, LA Jolla, CA) to cross link viral RNA. Heat inactivation was performed by heating 200 μL aliquots of viral stock at 1 × 109 pfu/mL for 20 min at 60°C. In vitro survival and synergy assays with docetaxel were performed as described above using PC3 cells to compare the activity of inactivated virus to live virus.
In vivo studies
All procedures were approved by United Kingdom Home Office (PL70/6521) and institutional boards. Mice were purchased from B&K Universal Ltd. The experiment was repeated three times, using six mice in each treatment group. Subcutaneous tumours were established in the flank of each mouse by injecting 1 × 107 PC3 cells in a volume of 100 μL Hanks Balanced Salt Solution (HBSS; Sigma-Aldrich). Animals were examined thrice weekly for tumour development. Three orthogonal tumour diameters (d1, d2, and d3) were measured using Vernier callipers and tumour volume was calculated from the formula V = π/6 d1·d2·d3. Animals were killed when tumour size exceeded 15 mm in any one dimension.
Once tumours were established and palpable, mice were randomly assigned to treatment groups and treated on days 0 and 3 with either reovirus or docetaxel alone or as a combined therapy. Reovirus (1 × 108 pfu in 100 μL volume) was administered using a single cutaneous puncture site. Once in a s.c. location, the 25-gauge needle was redirected along multiple tracks within the tumour to achieve maximal dispersal of the reovirus. Docetaxel (5 mg/kg) was administered intraperitoneally in a total volume of 100 μL. Vehicle control injections of 100 μL HBSS were administered in an identical manner to animals receiving single agent therapy and to control animals.
FACS analysis of cell survival and apoptosis
Following overnight seeding, PC3 cells were treated with 20 nM docetaxel and/or reovirus MOI 1 for 48 h. Adherent and non-adherent cells were collected, washed in cold PBS, re-suspended at 1 × 106 in 500 μL PBS and then incubated for 15 min at room temperature in the dark in cold 1 × binding buffer containing Annexin V-FITC antibody, according to manufacturer's instructions (Merck Biosciences Ltd). The cells were pelleted and re-suspended in cold 1 × binding buffer. Cells were stained with 10 μL propidium iodide (PI) at 30 μg/mL and analysed on a Coulter Epics XL flow cytometer (Beckman Coulter) using EXPO32 ADC software (Beckman Coulter).
Measurement of microtubule stability by Western blot analysis
PC3 cells were seeded overnight at 3 × 106 cells in 10 mL media in 10 cm Petri dishes and then treated with 5 nM docetaxel, reovirus at MOI 1, both, or neither for 48 and 72 h. Cells were washed twice in cold PBS and lysed in 500 μL cold RIPA buffer (Thermo Scientific) containing 5 μL of each of Halt protease inhibitor cocktail, phosphatase inhibitor cocktail and EDTA (Thermo Scientific). The samples were incubated on ice for 5 min prior to shearing of DNA by 3 to 4 passes through a 21ga needle. The samples were clarified by centrifugation and the supernatant was transferred to clean tubes and stored at -80°C prior to analysis by Western blot. Additional samples were collected from PC3 cells treated with paclitaxel (3.5 nM), cisplatin (1.25 μM), vincristine (40 nM) or doxorubicin (125 nM) alone or in combination with reovirus for 48 h.
Total protein (5 μg) was electrophoresed on 10% Bis-Tris gels (Invitrogen), transferred to polyvinylidene difluoride membranes, blocked, and exposed overnight to a mouse monoclonal acetylated α-tubulin primary antibody (6-11B-1, 1:30,000; Sigma-Aldrich) or mouse α-tubulin antibody (B-5-1-2, 1:50,000; Sigma-Aldrich) followed by incubation with a horseradish peroxidase labelled secondary antibody. Signal was developed using an Enhanced Chemiluminescence Plus Detection System (Amersham, UK).
Effect of low-dose docetaxel on virus production
PC3 cells were infected with reovirus (MOI 1) alone or in combination with 5 nM docetaxel. Samples were collected at 24, 48, 72 and 96 h post infection and following three cycles of freeze-thaw, were tested for viral titre by plaque assay of 10-fold serial dilutions on L929 cells.
Comparisons between groups were done using the 2-sided t-test and 2-way ANOVA. Statistical analysis was performed using GraphPad Prism 4 (GraphPad Software Inc.).
Reovirus cytotoxicity in PC3, Du 145 and LNCaP cell lines
Reovirus cytotoxicity is enhanced by combination with docetaxel
Synergistic interaction between reovirus and chemotherapeutic agents in PC3 and Du 145 prostate cancer cell lines
From this data we calculated combination indices (CI) and used isobologram analysis to determine whether this enhancement of cell death could be considered synergistic. The CI provides a quantitative measure of the degree of interaction between two or more agents. A CI of 1 denotes an additive interaction, >1 antagonism and <1 synergy.
Interaction of reovirus and chemotherapy on PC3a
0.41 ± 0.07
0.75 ± 0.04
1.58 ± 0.08
0.57 ± 0.01
0.40 ± 0.03
0.31 ± 0.04
0.46 ± 0.06
0.34 ± 0.05
0.44 ± 0.11
0.89 ± 0.06
0.51 ± 0.07
0.33 ± 0.05
0.49 ± 0.03
0.22 ± 0.03
0.11 ± 0.03
Interaction of reovirus and chemotherapy on Du 145a
1.02 ± 0.05
0.83 ± 0.03
0.75 ± 0.07
0.89 ± 0.06
0.70 ± 0.08
0.58 ± 0.10
0.80 ± 0.01
0.57 ± 0.05
0.44 ± 0.08
0.74 ± 0.13
0.61 ± 0.06
0.52 ± 0.06
0.82 ± 0.03
0.69 ± 0.03
0.59 ± 0.06
We then evaluated the effect of other chemotherapeutic agents on these two cell lines (Tables 1 and 2), looking at paclitaxel (another taxane), vincristine (a microtubule inhibitor), cisplatin (a pseudo-alkylating agent) and doxorubicin (a DNA intercalating agent). We observed synergistic cell kill with all agents, however CI values were slightly lower in PC3 cells than in Du 145.
Live virus is required for efficient cell killing
Live, heat inactivated and UV-inactivated reovirus was combined with docetaxel at a fixed ratio of 60 nM docetaxel to MOI 1 reovirus over five two-fold dilutions for 48 hours. The combination of live reovirus with docetaxel enhanced cell kill compared to docetaxel alone (2-way ANOVA p < 0.0001). This enhancement of cell kill was not apparent when heat inactivated or UV-inactivated reovirus was used (Figure 3b)
Combined reovirus and docetaxel treatment delays tumour growth in a PC3 xenograft murine model
In light of the observed in vitro synergy, the effects of combined reovirus and docetaxel on PC3 cells were evaluated in vivo in a nude mouse model. PC3 cells (1 × 107) were implanted subcutaneously in the flanks of nude mice and treatment was initiated when tumours reached an average diameter of 3 mm. Mice were treated with intratumoral reovirus, intraperitoneal docetaxel or both on day 0 and day 3. Control mice received the same tumour inoculum and were treated with an equivalent volume of HBSS i.t. and i.p. administered in an identical manner. There were no obvious toxic effects of single agent or combination treatments in all mice treated, and experiments were concluded as a result of tumour growth reaching 15 mm in any one dimension.
Enhanced apoptotic cell death with docetaxel and reovirus combination
Increased acetylation of microtubules following exposure to reovirus and docetaxel
Increased viral titre at early time points from cells exposed to reovirus and docetaxel compared to reovirus alone
The modest improved survival with docetaxel chemotherapy in recent studies has been a significant step forward in the treatment of hormone refractory metastatic prostate cancer (HRPC) but the overall poor prognosis and morbidity justifies the continued development of new treatment approaches [11, 12]. Although a number of oncolytic viruses have shown significant anti-tumour effects in phase I clinical studies [8, 9, 20, 21], their potential as main stream anti-cancer therapeutics will most likely be realised as combination therapy with other cancer treatment modalities. Theoretically, combination therapy could potentially allow reovirus to target drug or radiotherapy resistant subpopulations of tumour cells, or chemotherapy could be utilised to improve the biodistribution of oncolytic viruses.
In this study, we have demonstrated evidence of synergistic anti-cancer activity of oncolytic wild type reovirus with docetaxel in human prostate cancer in vitro and in vivo. In vitro synergy was further observed with other chemotherapeutic agents. The potential value of reovirus in combination with docetaxel was tested in a murine flank model of human prostate cancer. We did not observe any toxic effects in the treatment groups and while docetaxel alone had little effect on tumour progression at the dose used, reovirus alone had a modest effect. In combination however, there was significant inhibition of tumour progression.
Docetaxel and other members of the taxane family of chemotherapeutic drugs have been shown to stabilise microtubules in mitotic cells. Microtubules are essential for the separation of the duplicated chromatids to opposing poles prior to mitotic cell division. Stabilisation of microtubules impairs normal changes in microtubule structure, leading to a block in mitosis and promotion of apoptosis [22, 23]. The reoviral μ2 protein is an approximately 83 kDa protein encoded by the M1 genome segment. It forms a structurally minor component of the reovirus core and binds ssRNA and dsRNA [24–27]. It is also capable of binding to cellular microtubules [17, 28, 29]. It has been proposed that for some cell types, μ2-mediated recruitment of viral factories to microtubules might be necessary for efficient reovirus growth . We proposed that the presence of another agent also stabilising microtubules, could enhance these effects. We found that PC3 cells treated with reovirus in combination with docetaxel exhibited a considerable increase in microtubule acetylation compared to untreated or single agent treated cells. The same effect was observed with paclitaxel but not with doxorubicin or cisplatin which do not alter microtubule stability. Interestingly we found no enhancement of microtubule stability with vincristine, but this can be explained by the known mechanisms of action of the vinca alkaloids on tumour cells. The vinca alkaloids, such as vinblastine, vincristine, and vinorelbine, bind to the end of growing microtubules, blocking the addition of more tubulin dimers. The tubule cannot grow, but it can still disassemble, so the microtubules ultimately break down. The inhibition of tubular growth by vincristine would therefore not allow microtubule stabilisation, reovirus adherence and reoviral replication. However, our in vitro studies showed that the combination of vincristine and reovirus still resulted in synergistic cell kill suggesting some alternative mechanism. These findings provide further evidence of multiple mechanisms by which reovirus may combine with other anti-cancer treatments to enhance its antitumour effects. This broadens the potential clinical utility of reovirus very greatly. Although the data from PC3 cells was most compelling in terms of synergy by CI, we did see evidence of at least additive effects in DU145 with docetaxel and synergy with paclitaxel rather than antagonism. It would be important to evaluate the in vivo effects of combination with vincristine and paclitaxel to confirm the in vitro findings in future work. There would also be an opportunity to assess post-treatment tissue for reovirus replication and microtubule protein expression to compare our in vitro findings
In this study, we found an increase in viral titre at early time points in cells treated with the combined therapy. This has been noted previously for various non-small cell lung cancer cell lines treated with paclitaxel in combination with reovirus . At later time points, as the cells treated with docetaxel and reovirus became apoptotic and necrotic, the amount of virus recovered fell to levels less than from cells infected with reovirus alone.
Other chemotherapy/oncolytic virus combinations have also shown considerable promise. Recently, G47delta, an engineered oncolytic herpes simplex virus-1 was shown to have synergistic antitumour effects in vitro and in vivo in combination with taxanes through the enhancement of apoptosis . The adenovirus Onyx-015 enhanced clinical efficacy when used as intratumoral injection combined with systemic cisplatin and 5-fluorouracil (5FU) compared to chemotherapy alone . In preclinical models, synergy has been demonstrated with the combination of E1A-expressing adenoviral E3B mutants with cisplatin and paclitaxel , rat parvovirus H-1PV with gemcitabine  and oncolytic herpesviruses such as G207, HSV-1716, and NV1066 with various chemotherapeutic agents [35–37]. The mechanism underlying the observed synergy is incompletely understood and as in our study, not necessarily due to increased viral replication [38–40].
Recently completed phase I studies by our group and others using Reovirus type 3 (Dearing) have confirmed its potential as an anticancer agent as well as its safety and tolerability in humans [8, 9]. This has led to combination studies of systemic reovirus with a number of chemotherapeutic agents and radiotherapy as phase I studies (REO-). These include attempts to enhance cytotoxicity with gemcitabine (REO 09), docetaxel (REO10) and carboplatin/paclitaxel (REO11, REO15 and REO16) in a number of indications. The REO10 study showed the reovirus/docetaxel combination was safe and a maximum tolerated dose was not reached. Antitumor activity was seen with one complete response and three partial responses. A disease control rate (combined complete response, partial response, and stable disease) of 88% was observed. Immunohistochemical analysis of reovirus protein expression was observed in post-treatment tumor biopsies from three patients .
Reovirus has a potentially broad application as an anti-cancer therapeutic and oncolytic activity has been demonstrated in vitro, in in vivo murine models and in early clinical trials. Administration in combination with other modalities such as chemotherapy, targeted therapy and radiotherapy may be necessary in order to realize the full potential of reovirus, and indeed other oncolytic viruses.
We have demonstrated here and elsewhere  that co-delivery of reovirus with chemotherapeutic agents with a variety of modes of actions is able to enhance in vitro cytotoxicity in a synergistic manner. Our focus here was the interaction of reovirus with docetaxel, the standard of care first line chemotherapy agent for prostate cancer, on the highly metastatic human prostate cell line PC3. We showed that the combination therapy was synergistic in vitro, it was capable of slowing tumour growth and prolonging survival in a PC3 tumour mouse model. Microtubule stabilisation was enhanced in PC3 cells following treatment with combined reovirus/docetaxel combined therapy which may, in part, explain the mechanism of synergy. This data supports the positive clinical observations from the recent REO10 docetaxel/reovirus combination study.
We thank Kim Morton for expert technical assistance and Fiona Errington for her knowledge and advice.
Sources of funding:
LH - Oncolytics Biotech
GS - The Prostate Project
AB - The University of Surrey
TK - Mayo Clinic
KR - The University of Surrey
RV - Mayo Clinic
AM - Cancer Research UK
RP - Cancer Research UK
KH - Institute of Cancer Research
RM - University of Surrey
HP - University of Surrey
- Hashiro G, Loh PC, Yau JT: The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol. 1977, 54: 307-15. 10.1007/BF01314776.PubMedView Article
- Duncan MR, Stanish SM, Cox DC: Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol. 1978, 28: 444-9.PubMedPubMed Central
- Coffey MC, Strong JE, Forsyth PA, Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science. 1998, 282: 1332-4.PubMedView Article
- Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998, 17: 3351-62. 10.1093/emboj/17.12.3351.PubMedPubMed CentralView Article
- Strong JE, Lee PW: The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol. 1996, 70: 612-6.PubMedPubMed Central
- Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, et al: Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res. 2003, 63: 348-53.PubMed
- Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003, 3: 11-22. 10.1038/nrc969.PubMedView Article
- Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D, et al: A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008, 16: 627-32. 10.1038/sj.mt.6300403.PubMedView Article
- Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al: A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008, 14: 7127-37. 10.1158/1078-0432.CCR-08-0524.PubMedView Article
- Rowan S, Rachet B, Alexe DM, Cooper N, Coleman MP: Survival from prostate cancer in England and Wales up to 2001. Br J Cancer. 2008, 99 (Suppl 1): S75-7.PubMedPubMed CentralView Article
- Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004, 351: 1513-20. 10.1056/NEJMoa041318.PubMedView Article
- Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004, 351: 1502-12. 10.1056/NEJMoa040720.PubMedView Article
- Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991, 34: 992-8. 10.1021/jm00107a017.PubMedView Article
- Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 1993, 32: 2747-55. 10.1021/bi00062a003.PubMedView Article
- Eisenhauer EA, Vermorken JB, The taxoids: Comparative clinical pharmacology and therapeutic potential. Drugs. 1998, 55: 5-30. 10.2165/00003495-199855010-00002.PubMedView Article
- Babiss LE, Luftig RB, Weatherbee JA, Weihing RR, Ray UR, Fields BN: Reovirus serotypes 1 and 3 differ in their in vitro association with microtubules. J Virol. 1979, 30: 863-74.PubMedPubMed Central
- Kim J, Parker JS, Murray KE, Nibert ML: Nucleoside and RNA triphosphatase activities of orthoreovirus transcriptase cofactor mu2. J Biol Chem. 2004, 279: 4394-403.PubMedView Article
- Kobayashi T, Ooms LS, Chappell JD, Dermody TS: Identification of functional domains in reovirus replication proteins muNS and mu2. J Virol. 2009, 83: 2892-906. 10.1128/JVI.01495-08.PubMedPubMed CentralView Article
- Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.PubMedView Article
- Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al: Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9: 533-42. 10.1016/S1470-2045(08)70107-4.PubMedView Article
- Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J, et al: A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther. 2009, 8: 676-82. 10.4161/cbt.8.8.7913.PubMedView Article
- Rusan NM, Fagerstrom CJ, Yvon AM, Wadsworth P: Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin. Mol Biol Cell. 2001, 12: 971-80.PubMedPubMed CentralView Article
- Jordan MA, Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 1995, 4: 253-65. (2004)View Article
- McCrae MA, Joklik WK: The nature of the polypeptide encoded by each of the 10 double-stranded RNA segments of reovirus type 3. Virology. 1978, 89: 578-93. 10.1016/0042-6822(78)90199-X.PubMedView Article
- Mustoe TA, Ramig RF, Sharpe AH, Fields BN: Genetics of reovirus: identification of the ds RNA segments encoding the polypeptides of the mu and sigma size classes. Virology. 1978, 89: 594-604. 10.1016/0042-6822(78)90200-3.PubMedView Article
- Brentano L, Noah DL, Brown EG, Sherry B: The reovirus protein mu2, encoded by the M1 gene, is an RNA-binding protein. J Virol. 1998, 2: 8354-7. 7
- Coombs KM: Temperature-sensitive mutants of reovirus. Curr Top Microbiol Immunol. 1998, 233: 69-107.PubMed
- Parker JS, Broering TJ, Kim J, Higgins DE, Nibert ML: Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. J Virol. 2002, 76: 4483-96. 10.1128/JVI.76.9.4483-4496.2002.PubMedPubMed CentralView Article
- Yin P, Keirstead ND, Broering TJ, Arnold MM, Parker JS, Nibert ML, et al: Comparisons of the M1 genome segments and encoded mu2 proteins of different reovirus isolates. Virol J. 2004, 1: 6-10.1186/1743-422X-1-6.PubMedPubMed CentralView Article
- Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, et al: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer. 2009, 8: 47-10.1186/1476-4598-8-47.PubMedPubMed CentralView Article
- Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL: Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther. 2009, 16 (7): 551-60. 10.1038/cgt.2009.10.PubMedPubMed CentralView Article
- Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000, 6: 879-85. 10.1038/78638.PubMedView Article
- Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D, et al: E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther. 2008, 15: 40-50. 10.1038/sj.cgt.7701099.PubMedPubMed CentralView Article
- Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, et al: Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res. 2009, 15: 511-9. 10.1158/1078-0432.CCR-08-1088.PubMedView Article
- Chahlavi A, Todo T, Martuza RL, Rabkin SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999, 1: 162-10.1038/sj.neo.7900016.PubMedPubMed CentralView Article
- Post DE, Fulci G, Chiocca EA, Van Meir EG: Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther. 2004, 4: 41-51. 10.2174/1566523044577988.PubMedView Article
- Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK, et al: 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg. 2005, 9: 1068-77. 10.1016/j.gassur.2005.06.024. discussion 1077-9PubMedPubMed CentralView Article
- Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL: Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther. 1999, 10: 3013-29. 10.1089/10430349950016410.PubMedView Article
- Petrowsky H, Roberts GD, Kooby DA, Burt BM, Bennett JJ, Delman KA, et al: Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol. 2001, 75: 7050-8. 10.1128/JVI.75.15.7050-7058.2001.PubMedPubMed CentralView Article
- Adusumilli PS, Chan MK, Chun YS, Hezel M, Chou TC, Rusch VW, et al: Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther. 2006, 5: 48-53. 10.4161/cbt.5.1.2237.PubMedPubMed CentralView Article
- Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS: REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. Clin Cancer Res. 2010, 15;16 (22): 5564-5572.View Article
- Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R: Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res. 2009, 15 (19): 6158-66. 10.1158/1078-0432.CCR-09-0796.PubMedView Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/221/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.